The Nuclear Receptor Binding Protein 1 (NRBP1) antibody is a tool used to study the NRBP1 protein, a ubiquitously expressed adaptor protein implicated in regulating intracellular signaling and membrane trafficking. NRBP1 contains two ubiquitin-like (UBL) domains and a Src homology 3 (SH3) domain, enabling interactions with various partners, including CTNNB1 (β-catenin), APC, and kinases. It plays roles in Wnt/β-catenin signaling, cell proliferation, and vesicular transport, with dysregulation linked to cancers, neurodegenerative disorders, and metabolic diseases. Overexpression of NRBP1 has been observed in colorectal, breast, and ovarian cancers, suggesting its potential as a therapeutic target or biomarker.
Antibodies targeting NRBP1 are widely used in techniques like Western blotting, immunohistochemistry (IHC), and immunoprecipitation (IP) to investigate its expression, localization, and molecular interactions. These antibodies are typically raised in hosts such as rabbits or mice, with validated specificity for human, mouse, or rat NRBP1 isoforms. Commercial antibodies often include validation data (e.g., knockout cell line controls) to confirm target specificity. Researchers employ NRBP1 antibodies to explore its role in oncogenesis, particularly in pathways involving Wnt signaling and endosomal trafficking. However, variability in antibody performance (e.g., batch differences, cross-reactivity) necessitates careful experimental optimization and validation to ensure reproducibility in studies.